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Abstract
Background:  Because of the emerging intersections of HIV infection and Alzheimer's disease, we
examined cerebrospinal fluid (CSF) biomarkers related of amyloid and tau metabolism in HIV-infected
patients.
Methods: In this cross-sectional study we measured soluble amyloid precursor proteins alpha and beta
(sAPPα and sAPPβ), amyloid beta fragment 1-42 (Aβ1-42), and total and hyperphosphorylated tau (t-tau
and p-tau) in CSF of 86 HIV-infected (HIV+) subjects, including 21 with AIDS dementia complex (ADC),
25 with central nervous system (CNS) opportunistic infections and 40 without neurological symptoms and
signs. We also measured these CSF biomarkers in 64 uninfected (HIV-) subjects, including 21 with
Alzheimer's disease, and both younger and older controls without neurological disease.
Results: CSF sAPPα and sAPPβ concentrations were highly correlated and reduced in patients with ADC
and opportunistic infections compared to the other groups. The opportunistic infection group but not the
ADC patients had lower CSF Aβ1-42 in comparison to the other HIV+ subjects. CSF t-tau levels were high
in some ADC patients, but did not differ significantly from the HIV+ neuroasymptomatic group, while CSF
p-tau was not increased in any of the HIV+ groups. Together, CSF amyloid and tau markers segregated
the ADC patients from both HIV+ and HIV- neuroasymptomatics and from Alzheimer's disease patients,
but not from those with opportunistic infections.
Conclusions: Parallel reductions of CSF sAPPα and sAPPβ in ADC and CNS opportunistic infections
suggest an effect of CNS immune activation or inflammation on neuronal amyloid synthesis or processing.
Elevation of CSF t-tau in some ADC and CNS infection patients without concomitant increase in p-tau
indicates neural injury without preferential accumulation of hyperphosphorylated tau as found in
Alzheimer's disease. These biomarker changes define pathogenetic pathways to brain injury in ADC that
differ from those of Alzheimer's disease.
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Background
Central nervous system (CNS) infection is a nearly uni-
form feature of untreated human immunodeficiency virus
type 1 (henceforth, HIV) infection. Thus, from initial
viremia until death, HIV is detected in the cerebrospinal
fluid (CSF) of most patients not treated with combination
antiretroviral therapy [1-4]. While in its chronic phase
CNS infection is usually unaccompanied by neurological
symptoms or signs, this seemingly innocent exposure can
give way to more 'invasive' HIV encephalitis (HIVE) that
manifests clinically as the AIDS dementia complex (ADC;
also termed HIV-associated dementia), most commonly
in the context of more advanced systemic infection [5,6].
The salutary effects of potent antiretroviral therapy that
have transformed systemic infection from an almost
invariably fatal condition into a chronic disease amenable
to medical management with prolonged survival have
also had a major impact on its CNS manifestations. This
includes not only a marked reduction in the incidence of
CNS opportunistic infections, but a similar decline in
ADC/HIVE [7]. The latter parallels the potent effects of
antiretroviral therapy on CSF HIV RNA concentrations [8-
12].
The longer lifespan of patients on antiretroviral treatment
has raised questions of whether HIV infection might inter-
act with or even potentiate the development of Alzhe-
imer's disease [13-15]. Indeed, the pathogenesis of HIV-
related brain injury may intersect with Alzheimer's disease
in several aspects. Thus, some reports suggest that brain
amyloid deposition is increased in HIV infection, though
the extent and relation of this deposition to the clinical
state and regional HIV infection remain controversial [16-
19]. A CSF biomarker pattern similar to that in Alzhe-
imer's disease, with decreased CSF amyloid beta 1-42 frag-
ment (Aβ1-42) and increased CSF total tau (t-tau) [20,21],
has been reported in patients with ADC in one study [22].
Reports of elevated CSF t-tau and hyperphosphorylated
tau (p-tau) in ADC are conflicting, and while some previ-
ous studies have shown increased CSF levels in patients
with ADC [22,23], others have not [24,25].
In order to more clearly characterize changes in CSF
biomarkers in HIV infection related to CNS amyloid and
tau metabolism that are salient features of Alzheimer's
disease, we measured concentrations of two forms of sol-
uble amyloid precursor protein, alpha and beta (sAPPα
and sAPPβ), together with Aβ1-42, t-tau and p-tau in CSF of
untreated HIV-infected (HIV+) subjects with and without
ADC, along with HIV+ subjects suffering CNS opportun-
istic infections and HIV seronegative (HIV-) control
groups that included Alzheimer's disease patients and
both younger and older controls. Specifically, this study
tests the hypothesis that HIV infection induces a neurode-
generative process that from a biomarker perspective is
distinct from Alzheimer's disease.
Methods
Study design
This was a cross-sectional study using archived CSF speci-
mens from three clinical centers in Gothenburg, Sweden,
Milan, Italy and San Francisco, USA. The HIV+ subjects
selected included neuroasymptomatic, ADC and oppor-
tunistic infection groups who were either naïve to or off
antiretroviral treatment for at least 6 months at the time
of sampling. The HIV- subjects included younger controls
age-matched to the HIV+ subjects and older subjects with
or without Alzheimer's disease. Diagnoses of ADC and
each of the opportunistic infections were based on CDC
and American Academy of Neurology AIDS Task Force cri-
teria using standard clinical and laboratory evaluations
[26-28]. For CMV encephalitis and PML diagnosis, CMV
or JC virus DNA, respectively, was detected in CSF [29,30].
ADC was staged according to the Memorial Sloan-Ketter-
ing scale [5]. The diagnosis of Alzheimer's disease con-
formed to the National Institute of Neurological and
Communicative Disorders and Stroke - Alzheimer's Dis-
ease and Related Disorders Association (NINCDS-
ADRDA) criteria [31].
CSF samples were obtained under the auspices of research
protocols approved by the institutional review boards of
each of the study sites and in accord with the Helsinki
Declaration, either within the context of studies of the
natural history of HIV infection or during diagnostic eval-
uations [10]. All subjects gave their informed consent, and
if their capacity to provide consent was questioned, con-
sent was also obtained from those with power of attorney.
CSF and blood measurements
For the neural biomarker and HIV RNA assays, CSF was
collected and processed in polypropylene tubes, centri-
fuged after collection to remove cells, and supernatants
aliquoted and stored at -70°C until the time of the assay.
CSF concentrations of sAPPα and sAPPβ were determined
using the MSD®  sAPPα/sAPPβ Multiplex Assay as
described by the manufacturer (Meso Scale Discovery,
Gaithersburg, MD, USA). The samples were analyzed for
Aβ1-42, t-tau, and p-tau (phosphorylated at threonine 181)
by enzyme-linked immunosorbent assay (ELISA), as pre-
viously described [32-34]. All samples were analyzed
together in batch at the University of Gothenburg using
the same batches of reagents. Intra-assay coefficients of
variation were below 10% for all analyses. Previously
established laboratory cutoffs for Aβ1-42, t-tau and p-tau
were used for descriptive analysis.
HIV-1 RNA was quantified by the Roche Amplicor Moni-
tor assay (version 1.0 and 1.5, Hoffman La-Roche, Basel,BMC Neurology 2009, 9:63 http://www.biomedcentral.com/1471-2377/9/63
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Switzerland). Routine assessments also included CSF
white blood cell (WBC) count and peripheral blood
CD4+ T-lymphocyte (CD4) cell determination performed
in the local clinical laboratories using routine methods.
Statistical methods
Statistical significance of differences between groups was
assessed using either ANOVA with Tukey's post hoc test for
multiple comparisons or the Kruskal-Wallis test with
Dunn's post hoc test. Statistical tests were conducted both
with and without age adjustment. Spearman's Rank Cor-
relation Coefficient was used to evaluate correlations
among CSF variables, and linear regressions with 95%
confidence intervals were used in graphing selected inter-
actions. Receiver-operator characteristic (ROC) curve
analysis of diagnostic sensitivity and specificity was per-
formed for single variables. All these analyses used Prism
5 (Graphpad Software Inc, La Jolla, CA). Multivariate
analysis used the Principal Component Analysis (PCA)
algorithm implemented in the SIMCA-P+ software ver-
sion 11.0.0.0 (Umetrics AB, Umeå, Sweden) [35].
Results
Subjects
The background subject characteristics are summarized in
Table 1. They included: 40 HIV-infected without ADC
referred to as neuroasymptomatic subjects who were either
wholly without neurological symptoms or signs or
showed only mild neurological signs attributed to static
CNS conditions, all from San Francisco; 21 with a diagno-
sis of ADC (3 ADC stage 1 and 18 stage 2 - 4), all from
Milan except two from San Francisco; and 25 with major
CNS opportunistic infections - 4 with cytomegalovirus
encephalitis (CMV-E), 6 cryptococcal meningitis, 6 cere-
bral toxoplasmosis and 9 progressive multifocal leucoen-
cephalitis (PML) - all from Milan. The HIV- comparison
groups included 22 younger subjects from San Francisco,
21 subjects with Alzheimer's disease from Gothenburg,
and 21 older non-demented controls age-matched to the
Alzheimer's disease group from Gothenburg. The ages
were similar in the HIV+ groups and younger HIV- con-
trols in which males also predominated, but differed from
the Alzheimer's disease and older HIV- controls in which
ages were again similar and there was a higher ratio of
women. Among the HIV+ groups, the blood CD4+ T cell
counts were lower in the ADC and OI groups than in the
neuroasymptomatic group (P < 0.001 by post hoc testing)
and the latter also, as expected, differed from the younger
HIV- group (P < 0.01). While plasma HIV RNA levels were
higher in the ADC and OI groups than the neuroasympto-
matic group, this difference was not significant, though
CSF HIV RNA levels were higher in the two neurologically
afflicted groups compared to the neuroasymptomatic
group (P < 0.001).
Group differences in CSF biomarkers
Figure 1, panels A - E, show the subject group results for
each of the five CSF biomarkers (sAPPα, sAPPβ, Aβ42, t-
tau, and p-tau). All showed significant intergroup differ-
ences (ANOVA P < 0.0001), though the particular subject
group comparisons determining these differences varied
as indicated by post hoc testing. Table 2 summarizes the
statistical analysis of the clinically most relevant compari-
sons between the subject groups for each of the measured
amyloid and tau metabolites. Age adjustment did not
change any of the p-values, except that the statistical dif-
ferences between younger and older controls disappeared.
Amyloid metabolites
While they differed in magnitude, CSF concentrations of
sAPPα and sAPPβ (Figure 1A and 1B) exhibited similar
patterns across the subject groups. Both were markedly
reduced in the ADC and OI subjects compared to all the
other groups, including the HIV+ neuroasymptomatics as
well as the Alzheimer's disease patients and both HIV-
control groups (P < 0.001 for all). CSF Aβ1-42 concentra-
tions (Figure 1C) were less affected by HIV-related dis-
eases: in the ADC group Aβ1-42 varied widely, and among
Table 1: Subject Characteristics.
Number Gender Age Blood CD4 Blood HIV CSF HIV
years cells/μL RNA copies/mL
Subject Group (F:M) Mean (SD) Median (IQR)
HIV Infected
Neuroasymptomatic (NA) 40 6:34 41 (7) 431 (96) 4.36 (3.50 - 4.85) 3.38 (2.34 - 3.79)
ADC 21 5:16 38 (8) 74 (96) 5.25 (4.76 - 5.50) 5.40 (5.19 - 5.50)
OIs 25 4:21 38 (9) 79 (87) 5.05 (4.92 - 5.66) 4.36 (3.95 - 5.00)
HIV Uninfected
Cont y (HIV controls) 22 5:17 43 (7) 906 (265) ND ND
AD 21 12:9 65 (5) ND ND ND
Cont o (AD controls) 21 9:12 68 (5) ND ND ND
ND = not doneBMC Neurology 2009, 9:63 http://www.biomedcentral.com/1471-2377/9/63
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Amyloid and tau CSF biomarker concentrations in the different patient groups and their interactions Figure 1
Amyloid and tau CSF biomarker concentrations in the different patient groups and their interactions. Panels A-
E plot concentrations of different markers for the 6 subject groups. Boxes encompass interquartile ranges with median (line) 
and mean ("+"), while whiskers designate 10th to 90th percentiles. Results of statistical analysis of these data are given in Table 
2A. Panel F shows the principal component analysis (PCA) score scatter plot of subjects identified by disease grouping with the 
superimposed variable loadings of the biomarkers. The data in Panels A - E were used to construct a two-dimensional model 
along the two vectors. The individual subjects are represented by the small symbols as indicated in the key, and their placement 
is determined by the combination of their marker values in the model. The placement of the five variables (large symbols as 
indicated) gives information about how each affects the placement of the individuals in the plot, both with respect to direction 
along each vector axis and the relative magnitude of this effect as indicated by their distance from the origin. For example, high 
p-tau and low sAPPβ values contribute importantly to the position in the upper right and left quadrants, respectively. Note, 
however, that all variables influence where each subject is located in the plot so that the plot provides a visual representation 
of how the subjects are separated by the results of all five biomarkers. For more detailed information on methods, see refer-
ence [35]. Abbreviations: NA, HIV+ neuroasymptomatics; ADC, AIDS dementia complex; CNS OIs, CNS opportunistic infec-
tions; Contr y, younger HIV- controls; AD, Alzheimer's disease; Contr o, older HIV- controls.
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the HIV+ subjects only the opportunistic infection group
differed from the HIV+ neuroasymptomatics in this com-
parison. As expected, CSF Aβ1-42 concentrations in the
Alzheimer's disease patients differed from the older con-
trols (P < 0.01). However, CSF Aβ1-42 levels in the ADC
patients differed from neither the infections nor the
Alzheimer's disease groups.
Tau
CSF t-tau levels in the ADC group were elevated, but vari-
able (Figure 1D), and differed from the neuroasympto-
matics (P < 0.05) and younger HIV- controls (P < 0.001)
and the Alzheimer's disease group (P < 0.01) which was
higher, but not from the HIV+ opportunistic infections.
Higher t-tau concentrations in the Alzheimer's disease
group distinguished them from all the other groups except
the ADC patients. P-tau concentrations (Figure 1E) did
not differ among any of the HIV+ groups, nor did they dif-
fer from the younger HIV- controls, but these all differed
from the Alzheimer's disease group which had the highest
levels (P < 0.001). There was also an age effect, with the
older HIV- controls having higher levels of p-tau than the
younger controls (P < 0.01).
Principal component analysis
To assess how the combined effect of the five CSF biomar-
kers separated the subject groups, we applied principal
component analysis to the data set shown in panels A - E
of Figure 1. This analysis used all the groups and biomar-
ker measurements and segregated the groups into three
regions of the vector plot: one with the ADC and CNS OI
subjects, another with the Alzheimer's disease subjects,
and a third with the HIV+ neuroasymptomatics and HIV-
groups (Figure 1, panel F). Thus, as anticipated by the sim-
ilarity in the individual biomarker plots, the ADC and
opportunistic infections clustered together in the left
upper quadrant of the PCA plot. Likewise, the Alzheimer's
disease subjects aggregated separately into the right upper
quadrant, while the remaining subjects (neuroasympto-
matic and HIV- control groups) all intermixed principally
in the two lower quadrants. This analysis emphasizes the
similarity of ADC and opportunistic infections in their
effects on these neural markers, and their distinction from
the Alzheimer's disease, on the one hand, and the other
HIV+ and HIV- controls, on the other. The analysis of the
effect of the five variables on the model (designated by the
larger symbols in the Figure 1F plot) showed that the two
sAPPs had the greatest influence in segregating the ADC
and OI subjects, while Aβ1-42 exerted a smaller effect in the
same direction. By contrast, t-tau and particularly p-tau
were most important in the segregation of the Alzheimer's
disease patients.
Opportunistic infections
While the number of subjects with each of the four oppor-
tunistic infections was small, where the neural biomarkers
were altered in the overall group, they were generally
altered in the subgroups as well (Figure 2). Most notably,
concentrations of both sAPPs were reduced in all four
opportunistic infections in comparison to HIV+ neu-
roasymptomatic group (P ranging from < 0.05 to <
0.001), though there were no significant differences
among the four different infections (Figure 2A and 2B).
Reductions in CSF Aβ1-42 were also noted in all the oppor-
tunistic infections but were more variable, and only the
cryptococcal meningitis group differed significantly from
the neuroasymptomatic group (P < 0.05); again there
were no differences among the four infections (Figure
2C). T-tau elevations (Figure 2D) were notable in individ-
ual patients in the CMV-E, toxoplasmosis and PML
groups, but were also variable and none of the groups
were statistically different from the neuroasymptomatic
Table 2: Comparisons of CSF neural biomarkers across groups.
sAPPα sAPPβ Aβ1-42 t-tau p-tau
Overall ANOVA: < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Post Hoc Comparisons:
ADC vs NA < 0.001 < 0.001 ns < 0.05 ns
OIs vs NA < 0.001 < 0.001 < 0.001 ns ns
ADC vs OIs ns ns ns ns ns
NA vs Cont y ns ns ns ns ns
AD vs Cont o ns ns < 0.01 < 0.001 < 0.001
AD vs ADC < 0.001 < 0.001 ns < 0.01 < 0.001
Cont y vs Cont o < 0.05 ns ns ns < 0.01
ns = not significant
* All results were also compared using non-parametric Kruskal-Wallis test that yielded similar results. Statistical tests were also conducted with age 
adjustment, which did not change any of the results reported above, except for that differences between younger and older controls disappeared.BMC Neurology 2009, 9:63 http://www.biomedcentral.com/1471-2377/9/63
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group. P-tau levels (not shown) were similar across all of
the opportunistic infection groups, and none differed
from the HIV+ neuroasymptomatics.
Relationships among neural markers across subject groups
We also examined the correlations among the different
biomarkers across the subject groups, with particular
attention to the relationships within the amyloid pathway
and between the tau forms. Initial exploration showed sig-
nificant nonparametric correlations between the markers
in the same pathways (sAPPα vs sAPPβ, P < 0.0001, rs =
0.957; sAPPα vs Aβ1-42 P = 0.06, rs = 0.153; sAPPß vs Aβ1-
42 P < 0.05, rs = 0.195; t-tau vs p-tau P < 0.0001, rs = 0.462);
sAPPα and sAPPβ also correlated with t-tau, P < 0.0001, rs
= -0.644 and -0.736, and with p-tau P < 0.01 and P < 0.05,
rs = 0.170 and 0.237. Figure 3A shows the high correlation
of sAPPα and sAPPβ across the entire sample, indicating
that the concentrations of these two metabolites were sim-
ilarly altered by the different pathologies of the subjects.
While Aβ1-42 also correlated with sAPPs across their range,
the relationship was much looser. Figure 3B shows the
variability within each clinical group in the CSF Aβ1-42 in
relation to their CSF sAPPβ levels; this is perhaps most
notable at low (abnormal) sAPPβ concentrations where
the wide range of Aβ1-42 values was contributed by the
ADC and opportunistic infection patients. Results were
similar when Aβ1-42 was compared to sAPPα (Figure 3C).
In Figure 3D showing the relationship of p-tau to t-tau
CSF biomarkers in opportunistic infections Figure 2
CSF biomarkers in opportunistic infections. The results for each of the biomarkers in the four infection subgroups are 
compared to the results of the HIV+ neuroasymptomatic subjects. The symbols show individual results while bars show medi-
ans and, for the neuroasymptomatics, the interquartile ranges. Abbreviations: NA, HIV+ neuroasymptomatics; CMV-E, CMV 
enecephalitis; Crypto, cryptococcal meningitis; Toxo, cerebral toxoplasmosis; PML, progressive multifocal leukoncephalopathy.
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Selected marker correlations across patient groups Figure 3
Selected marker correlations across patient groups. The four panels show relationships between markers: Panel A 
between sAPPα and sAPPβ, Panel B between Aβ1-42 and sAPPβ, Panel C between Aβ1-42 and sAPPα, and Panel D between p-
tau and t-tau. Symbols for all four panels are defined in Panel A. The diagonal lines show linear regressions with 95% confidence 
intervals; each panel lists the P value and r2 for the regression. Abbreviations are those given in Figure 1.
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Table 3: ROC Curve Analysis of ADC Diagnosis.
sAPPα sAPPβ Aβ1-42 t-tau p-tau
Cutoff value: < 333 ng/mL < 205 ng/mL < 450 ng/L > 300 ng/L < 60 ng/L
All HIV+ subjects
Sensitivity 90,5 90,5 57,1 64,0 100,0
Specificity 56,3 58,4 47,7 61,3 4,6
ROC curve AUC 0,61 0,68 0,54 0,70 0,65
HIV+ excluding OIs
Sensitivity 90,5 90,5 42,9 64,0 100,0
Specificity 85,0 90,0 72,5 67,6 5,0
ROC curve AUC 0,88 0,95 0,57 0,74 0,70BMC Neurology 2009, 9:63 http://www.biomedcentral.com/1471-2377/9/63
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concentrations, the different diagnoses influenced the
regression in one or another direction - the elevated p-tau
in the Alzheimer's disease patients with high t-tau pulled
the right end of the line up, while the low p-tau in the
ADC and infection patients with elevated t-tau pulled it in
the opposite direction.
Diagnostic utility of CSF amyloid and tau biomarkers for 
ADC
To define initial values that might be used as diagnostic
'cutoffs' for sAPP concentrations in ADC and to evaluate
the utility of individual markers for ADC diagnosis in this
series, we plotted receiver-operator characteristic (ROC)
curves for each to compare their diagnostic sensitivity and
specificity in relation to the other subjects. Table 3 sum-
marizes results of analysis for each of the 5 biomarkers
and their diagnostic utility in ADC diagnosis compared to
all HIV+ subjects (neuroasymptomatic and opportunistic
infections) and to the neuroasymptomatics alone (exclud-
ing the opportunistic infections). The reason for examin-
ing these two types of comparisons (with and without
opportunistic infections) included: a) combined clinical
presentation and neuroimaging usually separates the
opportunistic infections from ADC before CSF is sampled,
and this separation may be further enhanced by CSF iden-
tification of opportunistic pathogens (e.g., by CMV and JC
virus DNA PCR and cryptococcal antigen); and b) it is
clear from the individual marker data and principal com-
ponent analysis in Figure 1 that these CSF biomarkers did
not distinguish the two neurologically abnormal groups.
This ROC curve analysis suggested initial diagnostic cut-
offs optimizing both sensitivity and specificity of 333 ng/
mL and 205 ng/mL for sAPPα and sAPPβ, respectively.
The results also showed that both sAPPs, used individu-
ally might be diagnostically useful as shown. For sAPPβ
both sensitivity and specificity were about 90 percent after
excluding opportunistic infections, whereas specificity
was lowered to less than 60 percent when the opportunis-
tic infections were included. By contrast, both Aβ1-42 and
t-tau were less helpful with relatively low sensitivity and
specificity even after excluding the opportunistic infec-
tions. As anticipated from the similar p-tau levels in all the
HIV+ groups, p-tau was not useful in establishing ADC
diagnosis in the infected group because of its extremely
low specificity. The relative utility of each of these markers
for ADC was reflected in the areas under the concentration
curve (AUC) values also listed in Table 2B, where a value
of 1.00 represents perfect accuracy and 0.50 is no differ-
ence from random diagnosis. Thus, in this series, sAPPβ
provided the most helpful marker of ADC after elimina-
tion of opportunistic infections.
Discussion
These results show that the CSF biomarkers of amyloid
and tau metabolism were abnormal in HIV-infected
patients with neurological diseases, but in a pattern that
differed from Alzheimer's disease. This difference implies
that different pathogenetic pathways underlie brain injury
in ADC and Alzheimer's disease, and that the ADC 'signa-
ture' provided by these combined markers might help in
diagnosis of HIV-related brain injury in untreated
patients. The reduction of sAPP levels in both ADC and
opportunistic infections also provides a clue to what may
be an important component of altered neuronal metabo-
lism in these conditions.
While the CSF biomarker profile has been adopted as a
clinical tool for Alzheimer's disease and may even be use-
ful in predicting incipient development of Alzheimer's
disease in those with mild cognitive impairment [36], a
similar approach has not been applied to the diagnosis of
ADC/HIVE, at least formally [37]. In Alzheimer's disease,
typical CSF changes include increases in t-tau and p-tau
and a decrease in Aβ1-42 [36,38]. The diagnostic accuracy
of these CSF biomarkers has been assessed in several stud-
ies, and their sensitivity and specificity in comparison to
cognitively normal elderly people are each approximately
90 percent [39]. The availability of this objective, labora-
tory-based approach contrasts with the clinical syndromic
basis of ADC/HIVE diagnosis [40]. While not supporting
a pathogenetic similarity of ADC/HIVE and Alzheimer's
disease or an Alzheimer's disease-like CSF biomarker pat-
tern in ADC/HIVE, these results do suggest that amyloid
and tau metabolism are perturbed in HIV-related brain
injury, and that combined measurement of CSF biomark-
ers may have clinical application in certain settings.
Amyloid metabolites
APP is an ubiquitously expressed transmembrane protein
that undergoes proteolytic processing by different secre-
tases, resulting in generation of metabolites with varying
potential pathological consequences (Figure 4) (for
review, Andreasson et al [41]). Cleavage by α-secretase
leads to production of soluble sAPPα that is shed from the
cell membrane and can diffuse into the CSF where its con-
centration can be measured. This process has been
referred to as the non-amyloidogenic pathway since it does
not generate pathogenic Aβ. By contrast, cleavage of APP
by β-secretase produces sAPPβ, also released and accessi-
ble to CSF for measurement, and β-CTF which, after fur-
ther cleavage by γ-secretase, forms Aβ peptides, including
Aβ1-42. In aggregated form, the latter is the major compo-
nent of Alzheimer's disease plaques and has been pro-
posed as one of the key molecules responsible for
neurodegeneration in Alzheimer's disease [38]. CSF levels
of sAPPα and sAPPβ are unaltered [42,43] or mildly ele-
vated in sporadic Alzheimer's disease [44]. The reduced
CSF Aβ1-42 concentration in Alzheimer's disease patients is
speculated to result from deposition of aggregates that areBMC Neurology 2009, 9:63 http://www.biomedcentral.com/1471-2377/9/63
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Figure 4 (see legend on next page)
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then sequestered in brain, preventing 'normal' levels from
reaching the ventriculo-subarachnoid space [45,46].
The mechanisms underlying the reduced CSF sAPPs in
both ADC and the opportunistic infections are uncertain
but may relate to the well-documented brain deposition
of APP in both frank HIVE and in brains without identi-
fied foci of HIV infection [47]. The parallel reduction of
sAPPs in ADC and opportunistic infections contrasts with
the reduction of CSF Aβ1-42 in Alzheimer's disease which
appears to be selective and independent of sAPPα or
sAPPβ levels. The overall correlation between both sAPPs
and Aβ1-42 was relatively weak, and the modest reduction
of Aβ1-42 noted in some ADC patients and the opportun-
istic infections might be secondary to earlier inhibition of
the APP pathway and limiting levels of the C-terminal
fragment of β-cleaved APP available as substrate for fur-
ther cleavage by γ-secretase rather than as a result of amy-
loid plaque deposition as in Alzheimer's disease. This is
also consistent with pathological studies showing that Aβ-
containing plaques characteristic of Alzheimer's disease
are not a common feature in HIV [16,17].
It should be noted, however, that this remains a contro-
versial issue [15]. Some studies report prevalence of 'dif-
fuse' amyloid plaques, not fulfilling the CERAD
neuropathological criteria for Alzheimer's disease [48] in
AIDS patients [15,18,19,49]. Recently Achim and col-
leagues [50] reported abundant Aβ immunostaining in
pyramidal neurons and along axonal tracts in brains of
HIV-infected subjects. They found higher levels of
intraneuronal Aβ immunoreactivity in HIVE than in HIV+
cases without this pathology. Double-labeling analysis
showed that the Aβ-immunoreactive granules in neurons
co-localized with lysosomal markers, and immunoelec-
tronmicroscopy showed Aβ was often found in structures
morphologically similar to autophagosomes. Most of
these studies used the 4G8 antibody that does not distin-
guish between Aβ and full-length APP, though a second
antibody, 82E1, that is more specific for Aβ was also tested
and said to show similar results. The earlier reports by
Nebuloni and colleagues [47] of accumulation of axonal
APP in proximity to foci of HIVE have also been con-
firmed in a simian immunodeficiency virus (SIV) model
of encephalitis [51]. It seems a reasonable hypothesis that
the reduction of soluble forms of APP in CSF may be
linked to the accumulation of APP in axons shown in
these studies, perhaps through alteration in processing,
transport or release of these forms into the extracellular
fluid.
The finding of decreased CSF sAPPs not only in ADC but
also in patients with various CNS opportunistic infections
indicates that the cause is not specific to ADC/HIVE
pathogenesis. Because immune activation, inflammation
and cytokine production are common to ADC and CNS
opportunistic infections, this broad category is a reasona-
ble starting point for future study. It is curious that both
meningitis without substantial brain parenchymal inva-
sion (related to cryptococcal infection) and focal brain
diseases (toxoplasmosis and PML) were capable of reduc-
ing CSF sAPPs, which presumably derive from throughout
the brain. Additionally, we have found a marked transient
reduction of CSF Aβ1-42 in bacterial meningitis [52], and
also recently detected significant reductions in sAPPs and
Aβ1-42 levels in multiple sclerosis [53], demonstrating that
this is not confined to the context of HIV infection. This
may all be taken as supporting a toxic effect of cytokines
or other molecules diffusing from sites of inflammation
to cause a generalized alteration in amyloid metabolism,
though this needs further study. It will be important to
more directly examine whether changes in sAPPs do
indeed correlate with CNS immune activation or particu-
lar components of inflammatory reactions both in human
diseases in vivo and in cell culture models that can be used
to dissect cause and effect. A further important subject for
exploration is whether these changes in amyloid metabo-
lism are harmful or protective.
Tau metabolites
CSF t-tau but not p-tau was elevated in some ADC patients
and the opportunistic infection group. The overall impres-
Hypothesis of alterations in amyloid metabolism in ADC and opportunistic infections compared to AD Figure 4 (see previous page)
Hypothesis of alterations in amyloid metabolism in ADC and opportunistic infections compared to AD. The dia-
gram shows proteolytic cleavages of the largest isoform of APP (APP770) and interprets the observed differences in effects of 
HIV and opportunistic infections from those of Alzheimer's disease on these pathways. In the non-amyloidogenic pathway (a.), 
cleavage by α-secretase occurs after residue 687, which enables the secretion of the large, soluble ectodomain of APP (sAPPα) 
into the medium and retention of the 83-residue C-terminal fragment (α-CTF) in the membrane. The α-CTF fragment can 
undergo cleavage by γ-secretase at residue 711 or 713 to release the p3 peptides (c.). In the amyloidogenic pathway (b.), β-
secretase cleaves after residue 671, which causes the secretion of the slightly truncated sAPPβ molecule and the retention of a 
99 residue C-terminal fragment (β-CTF). This fragment can undergo further cleavage by γ-secretase to release 40 or 42 ami-
noacid-long Aβ fragments (c.). Cleavage of both α- and β-CTF by γ-secretase releases the APP intracellular domain (AICD) 
into the cytoplasm. Hypothesized differences in the steps leading to CSF biomarker changes include: 1. an effect of CNS infec-
tion or immune activation on an early step in APP metabolism, in contrast to 2. deposition of Aβ1-42 in Alzheimer's disease[41].BMC Neurology 2009, 9:63 http://www.biomedcentral.com/1471-2377/9/63
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sion of t-tau in this series is that both ADC/HIVE and
opportunistic infections may increase t-tau leakage into
the CSF, but not consistently. The relatively modest
changes in t-tau levels in ADC, as compared to Alzhe-
imer's disease, may relate to the predominating subcorti-
cal pathology of ADC/HIVE [54], since tau is expressed
most prominently in non-myelinated cortical axons [55].
The inconsistency of t-tau elevations and the apparent
limited sensitivity of t-tau to detect this type of injury
likely also explain conflicts among previous reports.
CSF p-tau exhibited an even more consistent contrast
between HIV CNS diseases and Alzheimer's disease,
remaining at normal levels in the former and, as expected,
elevated in the latter. The observations of normal levels of
p-tau in all the HIV+ subjects are also consistent with the
lack of neurofibrillary tangles in ADC/HIVE, one of the
neuropathological hallmarks of Alzheimer's disease
[16,56]. Thus, while increases in brain tau deposition
have been reported in HIV infection, frank neuronal tan-
gles are an uncommon and inconsistent finding [57,58].
This difference further supports the broader concept that
ADC/HIVE and Alzheimer's disease do not share major
mechanisms of neuronal injury.
Application of neural biomarkers to diagnosis and patient 
management
The aggregate results of measurement of these neural CSF
markers suggest that the pattern of alterations in amyloid-
and tau-related markers may be useful in diagnosis of
ADC in certain settings. ADC in the developed world now
most frequently presents in patients who are not receiving
antiretroviral therapy, often also have a high prevalence of
background neurological abnormalities that can confuse
ADC diagnosis [11] and contrasts with the 'pure forms'
that allowed clinical definition of the condition earlier in
the epidemic [5,59]. There is thus an increasing need for
more objective, laboratory-based approaches to ADC/
HIVE diagnosis to supplement or displace simple clinical
recognition [40].
On the other hand, further studies will be needed before
these findings can be extended to the problem of treated
patients with cognitive dysfunction which now has
moved to the foreground as a major issue of neurological
diagnosis and treatment in the developed world [28]. The
increased lifespan conferred by treatment has highlighted
the importance of more subtle or indolent CNS injury
related to early viral invasion, persistent subclinical infec-
tion and continued immune activation acting alone or in
concert with other assaults on the CNS with age, including
Alzheimer's disease [13-15]. This needs to be addressed
directly by future studies focusing on these patients.
Limitations
This study was limited by its retrospective, cross-sectional
design and the use of a convenience sample. As different
subject groups came from different centers, it couldn't be
ruled out that they differed also in other aspects than diag-
nosis. To address some of the issues discussed here, partic-
ularly applicability to diagnosis, a prospective study
would be useful. A longitudinal study might also test the
use of these markers to predict the development of ADC
in those without clear symptoms. The study also did not
directly assess treated patients with milder cognitive dys-
function, nor did it include a substantial number of older
HIV-infected subjects in the years most vulnerable to
Alzheimer's disease. Finally, we did not assess HIV+
patients with known Alzheimer's disease, though we are
not aware of reports of patients with this combination of
conditions. Further studies are clearly needed before our
findings of distinct changes in sAPPs, variable elevations
in t-tau, and normal levels of p-tau can be applied diag-
nostically to treated patients with milder cognitive abnor-
malities [28].
Conclusions
These results clearly show that ADC and Alzheimer's dis-
ease are characterized by distinct CSF tau and amyloid
biomarker patterns suggesting distinct pathogenetic proc-
esses underlying the two conditions. The similar changes
associated with ADC/HIVE and CNS opportunistic infec-
tions suggest that they likely relate to CNS immune activa-
tion and inflammation. While the underlying mechanism
needs to be examined more directly in model systems and
using other approaches, these observations suggest that
the inflammation of HIV and other brain infections leads
to abnormal APP processing or transport in neurons and
axons, and that this may provide an indicator of an
important component of CNS injury.
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